Gamolenic acid - Scotia Pharmaceuticals
Alternative Names: Efamast; Efarmol; Epogam; Epogam Snip-Off capsules; Epostart; Gamma linolenic acid; Gamolenic acid/vitamin E; Primast; PrimogamLatest Information Update: 24 Oct 2021
At a glance
- Originator Scotia Holdings [CEASED]; Scotia Pharmaceuticals [CEASED]
- Class Small molecules; Unsaturated fatty acids
- Mechanism of Action Cell adhesion molecule inhibitors; Immunomodulators; Prostaglandin synthase stimulants; Thromboxane synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Atopic dermatitis
- Market Withdrawal Breast pain
- Discontinued Breast cancer; Rheumatoid arthritis
Most Recent Events
- 27 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
- 07 Oct 2002 The UK Medicines Control Agency has withdrawn the marketing authorisations for Evening primrose oil for atopic dermatitis (as Epogam) and mastalgia (as Efamast) in the UK